User Tools

Site Tools


glp-1analogs

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
glp-1analogs [2026/07/24 05:43] – [Adverse effects and C/I] gary1glp-1analogs [2026/07/24 05:44] (current) – [Adverse effects and C/I] gary1
Line 43: Line 43:
   *risk of [[hypoglycaemia]] is increased if the drug is used in combination with sulfonylureas or insulin   *risk of [[hypoglycaemia]] is increased if the drug is used in combination with sulfonylureas or insulin
   *increases risk of **diabetic retinopathy** by 50-80% (([[https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf]]))   *increases risk of **diabetic retinopathy** by 50-80% (([[https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf]]))
-  *increased risk of **permanent blindness by causing non-arteritic anterior ischaemic optic neuropathy (NAION)** (([[https://www.abc.net.au/news/2026-07-24/tga-vision-warning-glp1-ozempic-medication/106952900]]))+  *increased risk of **permanent blindness from non-arteritic anterior ischaemic optic neuropathy (NAION)** (([[https://www.abc.net.au/news/2026-07-24/tga-vision-warning-glp1-ozempic-medication/106952900]]))
     * typically presents as blindness suddenly upon waking and without pain     * typically presents as blindness suddenly upon waking and without pain
     * risk is also increased if they have diabetes, sleep apnea, hypertension or having a crowded optic disc     * risk is also increased if they have diabetes, sleep apnea, hypertension or having a crowded optic disc
glp-1analogs.txt · Last modified: 2026/07/24 05:44 by gary1

Donate Powered by PHP Valid HTML5 Valid CSS Driven by DokuWiki